Quia Pharma AB (publ) (STO:QUIA)
Sweden · Delayed Price · Currency is SEK 0.0035
+0.0001 (2.94%)
Aug 13, 2025, 3:25 PM CET
Quia Pharma AB Company Description
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform.
The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.
The company was formerly known as QuiaPEG Pharmaceuticals Holding AB (publ) and changed its name to Quia Pharma AB (publ).
Quia Pharma AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Quia Pharma AB (publ)
| Country | Sweden |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Marcus Bosson |
Contact Details
Address: Uppsala Business Park Uppsala, 754 50 Sweden | |
| Phone | 46 7 06 93 12 53 |
| Website | quiapeg.com |
Stock Details
| Ticker Symbol | QUIA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0001384850 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Marcus Bosson | MD, Chief Executive Officer and Director |
| Dr. Vidar Wendel-Hansen M.D., Ph.D. | Chief Medical Officer and Director |
| Hjordis Berg | Chief Financial Officer |
| Dr. Supaporn Sawadjoon | Head of Operations |